

ASX Release

Anatara receives R&D tax refund

BRISBANE, 14 October 2016: Anatara Lifesciences (ASX: ANR) is pleased to announce that it has received \$420,460 from the Australian Tax Office for the Research and Development (R&D) Tax Incentive. This refund is from Anatara's 2014-15 research activities and future refunds will increase significantly. The company is in the process of finalising its 2015-16 tax claim.

Dr Bridges said "the R&D tax rebate is an important source of non-dilutive funding for the company and will provide an ongoing source of valuable funds for the company's R&D initiatives. The refund further strengthens Anatara's Balance Sheet".

For more information please contact:

Investor inquiries	Media inquiries
Dr Mel Bridges Chairman & CEO, Anatara Lifesciences +61 (0) 413 051 600 mbridges@anataralifesciences.com	Jane Lowe IR Department +61 (0) 411 117 774 jane.lowe@irdepartment.com.au
Dr Tracey Mynott CSO, Anatara Lifesciences +61 (0) 405 050 113 tmynott@anataralifesciences.com	

About Anatara Lifesciences

Anatara Lifesciences (ASX: ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies. Please see www.anataralifesciences.com for further background.

For personal use only

